Treat-to-target and Improving Outcomes in Psoriasis: A Report from the GRAPPA 2014 Annual Meeting

Takeshita, Junko; Armstrong, April W.; Mease, Philip J.; Gelfand, Joel M.

doi:10.3899/jrheum.150128

Cited by 3 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7 From this evolved a treat-totarget (T2T) therapeutic framework for psoriasis which continues to be refined, pursuant to ongoing clinical research and the availability of new therapeutic options. [8][9][10][11] Although still emerging in the treatment of psoriasis, the tenets of T2T include the use of validated assessment tools and other disease severity scales to establish and regularly measure progress toward clinically relevant treatment outcomes, as well as to identify treatment modification strategies, if treatment targets are not achieved within appropriate timelines. 12 This approach thereby provides clinicians with practical guidance for assessing treatment outcomes and determining when to continue or modify therapy.…”

Section: Introductionmentioning

confidence: 99%

“…The notion that defining and tracking progress toward treatment goals could improve outcomes in psoriasis was introduced by a European consensus group in 2010 7 . From this evolved a treat‐to‐target (T2T) therapeutic framework for psoriasis which continues to be refined, pursuant to ongoing clinical research and the availability of new therapeutic options 8–11 . Although still emerging in the treatment of psoriasis, the tenets of T2T include the use of validated assessment tools and other disease severity scales to establish and regularly measure progress toward clinically relevant treatment outcomes, as well as to identify treatment modification strategies, if treatment targets are not achieved within appropriate timelines 12 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Management of moderate‐to‐severe plaque psoriasis with biologics: A treat‐to‐target position paper

Yeung

Bourcier

Gooderham

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Treat-to-target (T2T) recommendations for the use of systemic therapies (including biologics) in patients with moderate-to-severe plaque psoriasis have been published by a few groups of experts worldwide. However, there remains considerable variability in the choice of target severity measure and timing of milestones. To develop consensus recommendations for implementing T2T strategies for the management of moderate-to-severe plaque psoriasis using biologics. An expert group of Canadian

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Management of moderate‐to‐severe plaque psoriasis with biologics: A treat‐to‐target position paper

Yeung

Bourcier

Gooderham

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…75 The 2014 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) featured a panel discussion of T2T for the improvement of outcomes in psoriasis patients. 76 In that same year, a Canadian expert opinion paper was developed on T2T in plaque psoriasis, in which the authors recommended that a Physician Global Assessment (PGA) score of 0 (clear) be used as the treatment target. 60 A subsequent Canadian position paper presented T2T recommendations for the identification of T2T targets in psoriasis and PsA (Table 1).…”

Section: Introductionmentioning

confidence: 99%

Treating to Target(s) With Interleukin-17 Inhibitors

et al. 2019

View full text Add to dashboard Cite

Background: The treat-to-target (T2T) strategy has become established in several medical specialties as a key guidance to optimal therapeutic decision making. T2T may be effective in the assessment of the biologic class of agents called interleukin (IL)-17 inhibitors, which are emerging as a safe and effective treatment option for autoimmune inflammatory conditions such as plaque psoriasis, psoriatic arthritis (PsA), and ankylosing spondylitis (AS). Objective: The objective of this article is to use a T2T approach for the evaluation of the effectiveness and safety of IL-17 inhibitors in the management of patients with plaque psoriasis, PsA, and AS. Methods: Following a comprehensive literature search, a full-day meeting was convened to discuss and identify the T2T targets for psoriasis, PsA, and AS. Clinical trial evidence was presented for the approved IL-17 inhibitors—secukinumab, ixekizumab, and brodalumab—to assess whether these data meet T2T safety and efficacy targets. Results: All 3 approved agents were significantly superior to placebo and active controls in the achievement of T2T targets for psoriasis. Secukinumab and ixekizumab were likewise associated with significantly better outcomes than controls in the PsA targets, and secukinumab resulted in significant AS target improvements vs placebo. The IL-17 inhibitors were also associated with low rates of serious adverse events and exacerbations of common comorbid conditions. Conclusion: Phase III trial results support the T2T benefit and safety of IL-17 inhibitors according to their specific indications for the management of patients with plaque psoriasis, PsA, and AS.

show abstract

“…Finally, Joel Gelfand (Philadelphia, Pennsylvania, USA) chaired a presentation and discussion of the importance of treat-to-target strategies for managing psoriasis 13 . Finally, Joel Gelfand (Philadelphia, Pennsylvania, USA) chaired a presentation and discussion of the importance of treat-to-target strategies for managing psoriasis 13 .…”

mentioning

confidence: 99%

Prologue: 2014 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

Boehncke

Gladman²

2015

J Rheumatol

View full text Add to dashboard Cite

The 2014 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) was held in New York, New York, USA, and attended by rheumatologists, dermatologists, and representatives of biopharmaceutical companies and patient groups. Summaries of presentations at that meeting are introduced, including the GRAPPA-organized Fellows Symposium adjacent to the 2014 Swiss Psoriasis Day in Geneva. At the GRAPPA meeting itself, a Trainees Symposium was organized for rheumatology fellows and dermatology residents to present their research work; several patient research partners (PRP) organized Building Bridges, a session of interactive dialogue regarding the roles and responsibilities of PRP and researchers participating in working groups at GRAPPA and elsewhere; and 5 dermatology sessions were held to report on the international dermatology outcome measures group. Among the meeting topics were dermatologists' management of psoriatic arthritis (PsA); the unmet need for a comprehensive assessment tool for psoriasis; the Psoriasis Symptom Inventory; and the importance of treat-to-target strategies for managing psoriasis. Other presentations included an update of GRAPPA's research initiative to develop evidence-based criteria to identify inflammatory arthritis, enthesitis, dactylitis, and spondylitis; the utility of magnetic resonance imaging in PsA; a review of the PsA working group at OMERACT (Outcome Measures in Rheumatology); and updates on several GRAPPA educational projects. Considerable time was allotted to discussions of GRAPPA's efforts to update its treatment guidelines for PsA. (

show abstract

Treat-to-target and Improving Outcomes in Psoriasis: A Report from the GRAPPA 2014 Annual Meeting

Cited by 3 publications

References 39 publications

Management of moderate‐to‐severe plaque psoriasis with biologics: A treat‐to‐target position paper

Management of moderate‐to‐severe plaque psoriasis with biologics: A treat‐to‐target position paper

Treating to Target(s) With Interleukin-17 Inhibitors

Prologue: 2014 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

Contact Info

Product

Resources

About